goBalto making tracks with platform adoption

 

“There is intense pressure to speed clinical trials and restrain costs, but inefficiencies tied to complicated protocols, globalization and paper-based methods have stalled these efforts,” said Sujay Jadhav, goBalto’s CEO. “The current status of clinical trials has encouraged industry leaders to embrace cloud-based solutions. Our study startup methodology aligns with the goal of faster development by significantly impacting cycle times, leading to greater cost savings and faster market entry, making valuable therapies available to patients sooner.”

 

Activate is a purpose-built software-as-a-service application hosted in the cloud, and helps sponsors, CROs and trial sites get studies launched as quickly as possible.

 

goBalto touts a variety of ways in which its Activate service can support CROs, including data sharing, improving quality and reducing cycle time by 66 percent. The company asserts on its website that the Activate platform can help lower the average cycle time for CROs to complete registration documents from an average of 35 days to just 14. Activate also allows organizations to automate workflows to alert for and track when submissions are due, and offers workflow templates to help define the regulatory documents and submissions required for more than 60 countries.

 

So far this year, goBalto has released two new versions of Activate, with the first released March 23. That version was tailored to include submissions and other key activities and milestones that aren’t effectively managed under existing clinical systems, with new features that include expired document management, alerts that point out opportunities to improve cycle times and an API enhancement to support seamless integration with investigator portals, among others. The second update was announced July 7, with new features such as automatic/intelligent distribution of study documents and enhanced single sign-on enabling streamlined integration with adjoining customer systems, to name a few.

 

“Many of the steps involved in study startup create delays, but with the deployment of goBalto Activate, a proven, purpose-build cloud-based study startup solution, we can make a disruptive impact. Our partnership is critical to our goal of achieving automation in our clinical trials processes and our mission of cutting costs by shortening timeframes for developing therapies needed by patients worldwide,” Ross Pettit, senior vice president of clinical development operations at Infinity Pharmaceuticals, said in a news release.

 

In September, a two-year partnership was announced between goBalto and the Society for Clinical Research Sites (SCRS), a global trade organization dedicated to representing clinical research sites. Per the agreement, goBalto will participate as a Global Impact Partner (GIP), a position meant to support critical dialogue between clinical research sites and industry stakeholders. The company will also participate on the SCRS Global Impact Board at an executive level and work with the SCRS’ Leadership Council to develop and execute strategic initiatives for the organization.

 

“goBalto represents a handful of technology solution companies that have openly endorsed their commitment to clinical research sites,” Christine Pierre, president of SCRS, remarked of the partnership. “SCRS’ GIPs are focused on acknowledging the realities that today’s sites face, and actively addressing their challenges. goBalto is bringing technology disruptions to the cumbersome and inefficient clinical trial process, and we are proud to welcome them as our newest Global Impact Partner.”

 

Jae Chung, goBalto’s president and founder, added, “As a company dedicated to delivering innovative technologies that guide work and help standardize global processes by mitigating clinical risk and operational cycle times via ‘smart’ workflows, we recognize the critical role clinical research sites play as collaborators in fulfilling this mission.”